38,985 Shares in Pfizer Inc. $PFE Acquired by SG Trading Solutions LLC

SG Trading Solutions LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 38,985 shares of the biopharmaceutical company’s stock, valued at approximately $971,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Virtu Financial LLC grew its position in shares of Pfizer by 87.5% in the 4th quarter. Virtu Financial LLC now owns 477,207 shares of the biopharmaceutical company’s stock valued at $11,882,000 after buying an additional 222,761 shares during the last quarter. Blue Capital Inc. bought a new position in shares of Pfizer during the fourth quarter worth about $216,000. MV Capital Management Inc. acquired a new position in shares of Pfizer in the fourth quarter worth approximately $287,000. Cambient Family Office LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $531,000. Finally, White Knight Strategic Wealth Advisors LLC boosted its holdings in Pfizer by 68.5% in the fourth quarter. White Knight Strategic Wealth Advisors LLC now owns 25,036 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 10,174 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Finally, CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 for an external opportunity, prompting concerns about leadership continuity and execution at a time when investors are closely watching the company’s 2026 outlook. Reuters article
• Negative Sentiment: The market appears to be treating the CFO transition as a near-term uncertainty, with several reports noting that Pfizer’s shares fell as investors reassessed growth catalysts and financial stability. TipRanks article
• Neutral Sentiment: Pfizer named Cecile Guegan as interim CFO and said it is conducting a comprehensive search for a permanent replacement, which helps reduce uncertainty but does not fully remove investor concerns. Business Wire article
• Neutral Sentiment: The company reaffirmed its full-year 2026 guidance, which should limit downside if management can maintain operational momentum despite the executive transition. TipRanks article
• Positive Sentiment: Recent business updates, including progress on the obesity pipeline and a China partnership expansion, provide longer-term growth optionality, though they were not enough to offset today’s leadership-driven selloff. Yahoo Finance article

Pfizer Trading Down 2.6%

PFE opened at $25.25 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The firm has a market capitalization of $143.94 billion, a PE ratio of 19.28 and a beta of 0.34. The company’s 50-day moving average is $26.26 and its 200 day moving average is $26.33.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.